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Abstract
Background: Hepatic gene transfer, in particular using adeno-associated viral (AAV) vectors, has been shown to induce
immune tolerance to several protein antigens. This approach has been exploited in animal models of inherited protein
deficiency for systemic delivery of therapeutic proteins. Adequate levels of transgene expression in hepatocytes induce a
suppressive T cell response, thereby promoting immune tolerance. This study addresses the question of whether AAV gene
transfer can induce tolerance to a cytoplasmic protein.
Major Findings: AAV-2 vector-mediated hepatic gene transfer for expression of cytoplasmic b-galactosidase (b-gal) was
performed in immune competent mice, followed by a secondary b-gal gene transfer with E1/E3-deleted adenoviral Ad-LacZ
vector to provoke a severe immunotoxic response. Transgene expression from the AAV-2 vector in ,2% of hepatocytes
almost completely protected from inflammatory T cell responses against b-gal, eliminated antibody formation, and
significantly reduced adenovirus-induced hepatotoxicity. Consequently, ,10% of hepatocytes continued to express b-gal
45 days after secondary Ad-LacZ gene transfer, a time point when control mice had lost all Ad-LacZ derived expression.
Suppression of inflammatory T cell infiltration in the liver and liver damage was linked to specific transgene expression and
was not seen for secondary gene transfer with Ad-GFP. A combination of adoptive transfer studies and flow cytometric
analyses demonstrated induction of Treg that actively suppressed CD8
+ T cell responses to b-gal and that was amplified in
liver and spleen upon secondary Ad-LacZ gene transfer.
Conclusions: These data demonstrate that tolerance induction by hepatic AAV gene transfer does not require systemic
delivery of the transgene product and that expression of a cytoplasmic neo-antigen in few hepatocytes can induce Treg and
provide long-term suppression of inflammatory responses and immunotoxicity.
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Introduction
In the mid 1990s, in vivo gene transfer withviral vectors was either
inefficient for target cells that were not actively dividing (in the case
of retroviral gene transfer) or resulted in robust but only transient
gene expression because of cytotoxic T lymphocyte (CTL) responses
(in the case of adenoviral vectors). For example, first generation
adenoviral vectors carrying a LacZ reported gene yielded only
transient expression (less than 1 month) of the b-galacosidase (b-gal)
enzyme upon gene transfer to the liver or to skeletal muscle because
of CTL responses to b-gal and to viral antigens [1–4]. However, in
1996–7, four laboratories reported sustained expression of b-gal in
skeletal muscle fibers of immune competent animals using the same
CMV enhancer/promoter driven expression cassette delivered by
an adeno-associated viral (AAV) vector instead of adenovirus [5–8].
AAVgene transfer appearedmuchstealthier and did not activate b-
gal specific CTLs, nor did this vector contain viral coding
sequences. These findings sparked numerous investigations on
recombinant AAV, making it one of the most popular gene therapy
vectors, in particular for in vivo gene transfer [9–11]. AAV vectors
arederived from a non-pathogenicmember oftheparvovirusfamily
that is naturally replication deficient and is comprised of a 4.7-kb
single-stranded DNA genome packaged into a viral capsid. Recent
successes with AAV-mediated gene transfer include successful
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form of inherited blindness, correction of sarcoglycan deficiency in
skeletal muscle of dystrophic patients, and multi-year correction of
hemophilia in canine models by a single hepatic administration
[12,13].
A major concern in treatment of genetic disease is that the
therapeutic gene product, which is used to replace the endoge-
nous, non-functional or entirely absent protein, represents a novel
antigen to the immune system [14–19]. Therefore, adaptive
immunity may cause formation of antibodies or CTL responses
against this protein. The latter target the expressing cells, thereby
eliminating gene corrected cells. In the case of AAV-LacZ gene
transfer to skeletal muscle, subsequent studies showed that the b-
gal antigen was hidden from the immune system via an ignorance
mechanism, in part because of a lack of expression of the transgene
in antigen presenting cells (APCs), attributed to low in vivo
transduction efficiency of dendritic cells (DCs) and macrophages
with the AAV vector, and in part because of the cytoplasmic
localization of the gene product [4,20].
A number of recent studies have demonstrated induction of
immune tolerance to different protein antigens by hepatic gene
transfer. Hepatocyte-derived antigen can induce a regulatory
response, mediated by Treg, that actively suppresses humoral and
cellular immune responses [21–23]. In this context, AAV vectors
were found to be some of the most suitable vehicles for tolerogenic
transgene expression. However, tolerance induction by hepatic AAV
gene transfer has been predominantly, if not exclusively, described for
secreted or exocytosed proteins, resulting in systemic delivery of the
antigen for cross-correction ofa deficiency inother cell types or tissues
or for correction of a blood disorder. Although hepatic expression is
crucial for tolerance induction, systemic expression following
secretion from hepatocytes leads to antigen presentation in many
extra-hepatic sites, which could represent an important contributing
factor to tolerance induction [24–26]. We therefore asked the
question of whether expression of a non-secreted cytoplasmic antigen
from an AAV vector would induce immune tolerance.
We found that transgene expression in few hepatocytes (,3%)
from an AAV vector resulted tolerance induction to cytoplasmic b-
gal (rather than ignorance). Tolerized mice lacked antibody and
CTL responses to b-gal and contained Treg capable of suppressing
b-gal specific CD8
+ T cells. Substantial reduction of immunotoxicity
upon secondary gene transfer with an adenoviral vector expressing
b-gal correlated with increases of FoxP3
+ Treg frequencies.
Materials and Methods
Ethical statement
All animal work has been performed according to University of
Florida IACUC regulations.
Viral Vectors
AAV-LacZ vector (serotype 2) contained the b-gal cDNA under
transcriptional control of the hepatocyte-specific Duck Hepatitis B
Virus promoter [27]. This vector was produced by transient
transfection in HEK-293 cells, purified, and titered as previously
described. Vector doses are reported in vector genomes [vg; as
determined by quantitative slot blot hybridization] [28]. E1/E3-
deleted adenoviral vectors expressed green fluorescent protein
(Ad-GFP) or b-gal (Ad-LacZ) from the CMV I.E. enhancer/
promoter [19,29]. These vectors were produced in HEK-293 and
purified by CsCl gradient centrifugation using standard protocols.
Viral doses are reported as viral particles [vp] as determined by
absorbance measurement.
Animal experiments
Mice used in this study were the C57BL/6 strain from Jackson
Laboratories and FoxP3-IRES-EGFP knock-in mice on BALB/c
background. Foxp3-IRES-EGFP mice co-express EGFP and the
regulatory T cell-specific transcription factor Foxp3 as described
by others [30]. AAV-LacZ vector was delivered at 2610
11 vg/
mouse into the portal circulation by splenic capsule injection as
published [18]. Ad-LacZ or Ad-GFP was delivered at 1610
11
particles by tail vein injection (IV) to naı ¨ve mice or mice that had
received AAV-LacZ gene transfer 6 weeks earlier. Mice were
sacrificed at two different times after Ad administration depending
on the focus of the study: 10 days (immunotoxicity during acute
inflammation) or 45 days (for post inflammation status) after
adenoviral gene transfer (Fig. 1). Livers, spleens, and blood
Figure 1. Flow chart of experimental design. First, AAV2-LacZ hepatic gene transfer was performed. A secondary I.V. delivery of Ad-LacZ (or Ad-
GFP) was performed 6 weeks later or in naı ¨ve mice to provoke an immunotoxic response. Samples were taken and experiments were performed 10
and 45 days after Ad delivery. Splenic CD4
+CD25
+ T cells were adoptively transferred to naı ¨ve mice 6 weeks after AAV2-LacZ gene transfer or 10 days
after secondary Ad-LacZ delivery. Recipient mice were immunized with a peptide encoding the dominant CD8
+ T cell epitope for b-gal in this strain.
All animals were C57BL/6 mice.
doi:10.1371/journal.pone.0006376.g001
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groups of mice, animals were bled at Day 0, Day 14, and Day 28
to measure antibody titers against b-gal.
Adoptive T cell transfer
Spleens from viral vector transduced C57BL/6 mice were
harvested into 2-MLC media (DMEM, 2% heat-inactivated fetal
calf serum, 1 mM sodium pyruvate, 10 mM HEPES, 0.1 mM
non-essential amino acids, 10
26 M 2-mercaptoethanol, and
antibiotics) at room temperature, homogenized, filtered through
a 70-mm cell strainer, and centrifuged at 300 g for 10 min. Cells
were subsequently incubated with ACK lysing buffer (BD
Bioscience) for 5 min and washed twice with 2-MLC medium.
Viable splenocytes were counted with a hemacytometer and
trypan blue. The CD4
+CD25
+ T cell isolation kit (Miltenyi,
Auburn, CA) was used to purify Tregs from bulk splenocytes by
magnetic cell sorting as described [25]. Purified CD4
+CD25
+ cells
were pooled for each experimental group of donor mice and
delivered to naı ¨ve C57BL/6 mice at 1610
6 by tail vein injection
(Fig. 1). Recipient mice were immunized with 5 mg of the
DAPIYTNV (the b-gal dominate CD8
+ T cell epitope in
C57BL/6 mice [31]) emulsified in Complete Freund’s Adjuvant
(CFA) by 4 dorsal subcutaneous injections 24 hours after adoptive
transfer. Mice were sacrificed 14 days after challenge to determine
frequencies of IFN-c T cells by ELISpot.
Measurement of CD4
+CD25
+Foxp3
+ T cell frequencies by
flow cytometry
Splenocytes were isolated as described above. Nuclear Stain for
transcription factor FoxP3 was performed with the BD Biosciences
(San Jose, CA) kit. Briefly, splenocytes (1610
6 per mouse) were
stained with fluorescent conjugated antibodies, including anti-
mouse CD4 - pacific blue (channel 6), anti-mouse CD25 - PE
(channel 2) and anti-mouse FoxP3 - Alexa FluorH 647 (channel 4)
according to BD Biosciences staining protocol. Frequencies of
CD25
+Foxp3
+ cells among total CD4
+ splenocytes were assessed
by FACS analysis using LSR-II instrumentation from BD
Biosciences (San Jose, CA) and the CELLQUEST software.
ELISpot for IFN-c secreting cells
Splenocytes were isolated 14 days after either IV challenge with
Ad-LacZ or subdermal challenge with the CD8
+ b-gal dominant
epitope, and cultured for ELISpot analysis. ELISpot was
performed as previously described [15]. A 96 well ELISpot
culture plate (Millipore, Billerica, MA) was pretreated with an
IFN-c capture antibody (BD Biosciences, San Jose, CA) overnight
at 37uC in 10% CO2 at 1:60 dilution in 100 ml of culture media
(DMEM media with 5% FBS and 1% pen/strep). After overnight
incubation, the wells were blocked using PBS with 5% sucrose and
1% BSA for 2 hours at room temperature. Subsequently, 1610
6
splenocytes were added in triplicate and cultured in a final volume
of 200 ml of media for 30 hours at 37uC in 10% CO2. The
stimulation media contained 5 mg/ml of the CD8
+ b-gal dominant
epitope or 250 viral paricles per cell of heat-inactivated (1 hour at
60uC) Ad-F.IX. Positive control stimulation media contained
10 mg/ml of Staphylococcal Enterotoxin B (SEB) super antigen,
and mock media was the culture media without additional antigen.
After stimulation, the wells were rinsed, and a secondary detection
IFN-c antibody at 1:60 dilution in 100 ml filtered PBS with 1%
BSA was added overnight at 4uC. Detection utilized HRP
streptavidin (BD Biosciences, San Jose, CA) at 1:60 dilution in
100 ml PBS/10% FBS for 2 hours at room temperature, followed
by color development with 100 ml of BCIP/NBT chromogen (BD
Biosciences). IFN-c producing cells were analyzed and counted
with the CTL-ImmunoSpotH S5 UV analyzer (Cellular Technol-
ogy, Shaker Heights, OH).
b-galactosidase enzymatic staining in mouse liver
sections
Liver samples were fixed (n=4/group) for 2 hours in 4%
paraformaldehyde, rinsed in PBS, and frozen in OCT compound
(using a 90% isoproponal dry ice bath) and stored at 280uC until
sectioned. OCT blocks were sectioned (8 mM) with a cryostat,
fixed for 10 min with cold acetone (4uC), rinsed with PBS, and
immersed in b-gal enzyme activity stain buffer (X-gal buffer) at
37uC for 8 hours. Slides were rinsed with PBS and later stained
with hemotoxylin for nuclear detection in order to determine the
percentage of hepatocytes that stained positive for b-gal activity.
X-gal buffer consisted of PBS with 2 mM MgCl2,3 0 m M
K3Fe(CN)6,3 0m MK 4Fe(CN)6, and 1 mg/ml x-gal. For each
liver, 5 random fields of view (at a total magnification of 100X)
from 3 different sections separated by 24 microns where captured
by the Nikon Eclipse 80i microscope equipped with a Photometric
CoolSnap camera. The mean percentage of hepatocytes produc-
ing b-gal from these images was calculated using Pro Image
Software.
H&E staining and scoring of hepatic inflammation
OCT blocks were sectioned (8 mM) with a cryostat, fixed for 10
minutes with 4uC acetone, rinsed with PBS and stained by H&E
(hemotoxylin & eosine). Slides were reviewed by one observer,
blinded to treatment group, using the following scale to score
inflammation within the liver parenchyma and portal ducts:
0=none; 1=focal, mild lesions; 2=multifocal, moderate lesions;
3=multifocal, severe lesions; 4=multifocal degeneration or
necrosis.
Immunofluorescence staining of mouse liver sections
Livers samples from each group (n=4/group) were frozen in
OCT compound and sectioned as described above. Sections on
slides were fixed for 10 min with room temperature acetone,
allowed to dry for 30 minutes (to permeabilize the cells), rinsed
with PBS, and stained with immunoflourescently labeled antibod-
ies against CD8 and b-gal. Staining was performed by blocking
with PBS with 5% goat serum for 1 hr at room temperature in a
humidity chamber. Rat anti-mouse CD8a (eBiosciences, San
Diego, CA) and rabbit anti-b-gal (Invitrogen, Carlsbad, CA) were
added at 1:100 and 1:1000 dilution, respectively, in PBS/1% goat
serum and incubated in a humidity chamber at 4uC overnight.
Fluorescent conjugated goat anti-rat IgG Alexa FluorH 568
(Invitrogen, Carlsbad, CA) and goat anti-rabbit IgG Alexa FluorH
488 (Invitrogen, Carlsbad, CA) were added at 1:200 and 1:1000,
respectively, and incubated for 1 hr at room temperature in a
humidity chamber. Slides were mounted with fluoromount media
(Fisher Scientific), and staining was captured using a Nikon Eclipse
80i fluorescent microscope equipped with a Photometric Cool-
Snap camera. Five random fields of view at 200X from 3 different
sections separated by 24 microns were used to determine the level
of CD8
+ and b-gal
+ staining. The ratio of hepatocytes producing
the transgene product and CD8
+ cells was determined using Pro
Image Software.
Liver enzyme levels
Blood was collected and plasma isolated from mice at day 10
after Ad I.V. gene transfer to determine level of ALT (alanine
aminotransferase) and AST (aspartate aminotransferase), which
Hepatic Tolerance Induction
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measured by the clinical chemistry lab at the small animal
hospital affiliated with the University of Florida Veterinary
Program (Gainesville, FL).
Antibody levels against b-gal
Blood was collected from AAV-LacZ only, Ad-LacZ only, and
AAV-LacZ plus Ad-LacZ transduced mice at Day 0, Day 14, Day
28 and Day 45 after IV delivery of Ad-LacZ. IgG1 and IgG2a
immunocapture assays to determine antibody titers against b-gal
was performed as follows. ELISA plates were coated with 1 ng/ml
of recombinant b-gal protein (Sigma, St Louis, MO) overnight at
4uC. In parallel, 2-fold serial dilutions of mouse IgG1 or IgG2a
(Sigma) were used to coat wells for standard curve. Blocking was
done with dilution buffer (PBS containing 5% BSA and 0.05%
Tween20) for 1 hr at room temperature. Samples were added at
1:20 for 2 hours at 37uC. Goat anti-mouse IgG1 or IgG2a HRP-
conjugated secondary antibody (Southern Biotech, Birmingham,
AL) was added at 1:2000 in dilution buffer for 2 hours at 37uC.
Detection was done using SIGMAFAST
TM OPD tablets (Sigma).
Absorption (OD450) was measured using the Model 680 micro-
plate reader (Bio-Rad, Hercules, CA).
Statistics
Statistical comparisons between experimental groups were
performed by two-tailed Student’s t test. Values were considered
to be statistically significant for P,0.05.
Results
Protection of b-gal expression in hepatocytes following
AAV gene transfer
In previous studies, we have demonstrated induction of immune
tolerance to coagulation factor IX (F.IX) by hepatic AAV gene
transfer [22]. In this study, we chose b-gal as a model antigen for a
cytoplasmic expressed protein. Gene transfer was performed in
C57BL/6 mice for the following reasons. This strain mounts
effective CD8
+ T cell responses against b-gal expressing cells (such
as hepatocytes or myofibers) upon adenoviral gene transfer; it is
known that following AAV gene transfer to skeletal muscle, lacZ
expression in myofibers of C57BL/6 mice persists because of
ignorance but is eliminated by a CTL response upon secondary
gene transfer with Ad-LacZ; the immunodominant CD8
+ T cell
epitope for b-gal is known [3,4,31–34]. An outline of our
experimental approach is described in Fig. 1.
Figure 2. Expression of b-gal in viral vector transduced livers. Sections from C57BL/6 mice (3 per animal; separated by 24 microns) were
stained for b-gal enzyme activity and counterstained with hemotoxylin nuclear stain. A. Representative images of livers from AAV-LacZ transduced
mice (6 weeks or 12 weeks after gene transfer); AAV-LacZ/Ad-LacZ transduced mice (10 days or 45 days after Ad-LacZ administration, which occurred
6 weeks after the initial AAV-LacZ gene transfer); and Ad-LacZ only transduced mice (10 and 45 days after gene transfer). Arrows point toward
examples of b-gal
+ hepatocytes in AAV-LacZ only transduced livers. Original magnification: 100x. B-C. Percentages of b-gal expressing hepatocytes at
day10 (B) or day 45 (C) after Ad-LacZ gene transfer. Data are average6SD for n=4 mice/experimental group.
doi:10.1371/journal.pone.0006376.g002
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tolerance to a cytoplasmic transgene product and to protect
against immunotoxic responses was explored. AAV-LacZ trans-
duced livers showed a low level of transgene expression in 1–3% of
hepatocytes when analyzed 45 days after gene transfer (Fig. 2). Ad-
LacZ gene transfer resulted in transient high-level b-gal activity
(40–75% of hepatocytes) at 10 days, which, as expected, declined
to undetectable by 45 days (Fig. 2A-C). In contrast, livers initially
transduced with AAV-LacZ had b-gal expression in 35–78% of
hepatocytes and continued to express in a range of 4%–14% when
analyzed 45 days after secondary gene transfer with Ad-LacZ
(which was performed 45 days after AAV-LacZ transduction).
These results demonstrate that a portion of the additional b-gal
expression introduced by the more effective but highly immuno-
genic Ad-LacZ vector remained protected. This is in contrast to
findings by others on muscle gene transfer, showing that secondary
Ad-LacZ gene transfer eliminates previously AAV-LacZ trans-
duced skeletal muscle fibers [4].
Reduction of Ad-LacZ induced immunotoxicity by prior
transduction with AAV-LacZ
Since we observed partial protection of Ad-LacZ transduced
hepatocytes, we decided to assess the level of hepatotoxicity
induced by Ad-LacZ in naı ¨ve control and AAV-LacZ pre-treated
mice (n=4 per group) by assessment of liver inflammation and
measuring the systemic levels of liver enzymes as indicators of
liver damage. In mice that had received AAV-LacZ only, there
were 2 cases of mild inflammation and 2 cases of moderate
inflammation in the parenchyma, and 4/4 animals had only mild
inflammation in the portal ducts (Fig. 3A, B, I, J). All (4/4) Ad-
LacZ only transduced livers presented with severe inflammation
in the parenchyma and 2 cases of moderate and 2 cases of severe
Figure 3. Liver inflammation. Liver sections were stained with H&E to determine levels of inflammation in the parenchyma and portal ducts at 10
days after and Ad-LacZ or Ad-GFP gene delivery to naı ¨ve mice or mice that had received AAV-LacZ gene transfer 6 weeks earlier. AAV-LacZ only
transduced mice are shown for comparison (n=4 per experimental group). A-H. Representative images at original magnification of 50x and 100x
illustrate degrees of inflammation from AAV-LacZ, AAV-LacZ/Ad-LacZ, AAV-LacZ/Ad-GFP and Ad-LacZ only groups. A trained pathologist scored the
liver inflammation in parenchyma (I) and portal ducts (J) in a blinded fashion to accurately determine the level of inflammation in the groups. Bars
represent scores for livers of individual animals.
doi:10.1371/journal.pone.0006376.g003
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control groups transduced with Ad-GFP vector only or receiving
AAV-LacZ followed by Ad-GFP showed similar levels of severe
inflammation (Fig. 3E, F, I, J). The AAV-LacZ/Ad-LacZ group,
however, showed 4 of 4 livers with moderate inflammation in the
parenchyma and 3 cases of moderate and 1 case of mild
inflammation in the portal ducts (Fig. 3 C, D, I, J). In summary,
these results reflected a level of inflammation that was
intermediate between AAV-LacZ only and Ad-LacZ only treated
mice.
Systemic ALT and AST levels, indicators of liver damage, were
within normal range (40 U/L and 70 U/L, respectively) in the
AAV-LacZ only group (Fig. 4). In the AAV2-LacZ/Ad-LacZ
group, ALT levels were elevated to 250 u/L and AST levels
elevated to 225 U/L, but were significantly reduced compared to
the AAV-LacZ/Ad-GFP, Ad-LacZ only, and Ad-GFP only
groups, which were 350 u/L (ALT) and 325–375 U/L (Fig. 4).
These measurements were performed on plasma samples obtained
10 days after adenoviral gene transfer.
Severity of CD8
+ cellular infiltrates in liver parenchyma
It is known that administration of a first generation adenoviral
vector causes CD8
+ T cell responses against transgene product and
viral antigens encoded by the vector backbone. Co-staining of
CD8
+ cells and transgene expressing cells (either b-gal or GFP)
was used to determine levels of CD8
+ cellular infiltrate at the sight
of transgene production at 10 days after Ad-LacZ or Ad-GFP
vector delivery. Immunofluorescent detection showed close to a
2:1 ratio of CD8
+ cells to either b-gal
+ or GFP
+ hepatocytes in
livers of Ad-LacZ, Ad-GFP, or AAV-LacZ/Ad-GFP transduced
mice, while this ratio was 0.2:1 in the AAV-LacZ/Ad-LacZ group.
Therefore, this difference represents a 10-fold decrease in the
CD8
+ cellular infiltrate in the AAV-LacZ/Ad-LacZ mice (Fig. 5).
Taken together, the results shown in Figs. 2–4 demonstrate that
tolerance induction to b-gal by AAV gene transfer substantially
reduces transgene product-directed immunotoxicity and that the
reduction of adenoviral gene transfer-induced liver toxicity and
hepatic CD8
+ T cell infiltrate is linked to b-gal transgene
expression. Toxicity and T cell responses to the liver remain high
in secondary gene transfer with an Ad vector expressing a different
transgene product.
Humoral response to b-gal
Ad-LacZ transduced mice on average produced 500–700 ng/
ml plasma of IgG1 anti-b-gal at days 14, 28, and 45 after gene
transfer (Fig. 6). No IgG2a anti-b-gal was detected (data not
shown; this is different from muscle-directed Ad-LacZ gene
transfer, which results in IgG2a formation) [19]. In contrast, both
AAV-LacZ only and AAV-LacZ/Ad-LacZ transduced mice failed
to form antibodies against b-gal (Fig. 6).
Inflammatory cytokine (IFN-c) production by T cells
In order to quantify the effect of tolerance induction on
activation of pro-inflammatory subsets of T cells, ELISpot assays
were performed 14 days after Ad-LacZ gene transfer to naı ¨ve or
AAV-LacZ pre-treated mice. Splenocytes from individual mice
were re-stimulated in vitro with b-gal, the immunodominant b-gal
CD8
+ T cell epitopes, or heat-inactivated adenoviral particles.
Frequencies of IFN-c secreting cells were measured for Ad-LacZ
mice only and AAV-LacZ/Ad-LacZ treated mice (Fig. 7A). AAV-
LacZ only mice served as an additional control. Ad-LacZ induced
a robust CD8
+ T cell response to b-gal (9-fold above the frequency
in mock-stimulated cultures), which was nearly undetectable in
AAV-LacZ or AAV-LacZ/Ad-LacZ transduced animals. Similar
results were obtained for the IFN-c
+ response to entire b-gal
protein antigen (Fig. 7A). Ad-lacZ only and AAV-LacZ/Ad-LacZ
transduced mice showed an IFN-c
+ response to adenoviral
particles, which was somewhat reduced in the AAV-LacZ/Ad-
LacZ group (Fig. 7A). All splenocyte cultures showed equally high
responses to control stimulation with super antigen (Fig. 7B).
Induction of Treg by AAV-LacZ gene transfer
Adoptively transferred CD4
+CD25
+ splenocytes from AAV-
LacZ and AAV-LacZ/Ad-LacZ but not Ad-LacZ transduced mice
were able to significantly suppress the IFN-c
+ response against the
dominant b-gal CD8
+ T cell epitope when compared to non-
specific Treg transferred from naı ¨ve mice (Fig. 7C). In contrast,
IFN-c
+ responses to control stimulation with super antigen were
not suppressed (Fig. 7D).
Furthermore, we found that the frequency of CD25
+Foxp3
+
Treg among CD4
+ T cells was significantly increased in AAV-
LacZ transduced mice following secondary Ad-LacZ gene transfer
(Fig. 8A,B), which was not seen for secondary gene transfer with
Ad-GFP control vector. Ten days after adenoviral gene transfer,
the percentages of Treg were lowest in spleens of those mice that
had been transduced with adenoviral vectors only, irrespective of
the transgene.
Figure 4. Systemic levels of liver enzymes as indicators of liver
damage. Systemic levels of AST (aspartate aminotransferase) and ALT
(alanine aminotransferase) liver enzyme levels were measured from
plasma for all experimental groups of C57BL/6 mice 10 days after Ad-
LacZ or Ad-GFP delivery (i.e. during the acute inflammatory response in
the liver) and compared to data from AAV-LacZ transduced mice that
did not receive Ad vectors. Data are average6SD for n=4 mice/
experimental group.
doi:10.1371/journal.pone.0006376.g004
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liver, which is technically more challenging. Therefore, utilized
FoxP3 reporter mice (FoxP3-IRES-EGFP knock-in mice) to
analyze for frequencies of Treg in form of EGFP
+ intrahepatic
lymphocytes 10 days after Ad-LacZ gene transfer. In AAV-LacZ
pre-treated mice, the frequencies of Treg were significantly
increased compared to AAV-LacZ transduced mice that did not
receive the secondary gene transfer (Fig. 8C), while Treg were
undetectable among hepatic lymphocytes from Ad-LacZ only
treated mice.
Discussion
Hepatic gene transfer with AAV vectors has been shown to
induce tolerance to a number of transgene products in animal
models of human disease. This treatment provided immune
tolerance to the therapeutic protein and, simultaneously, therapy
or, alternatively, allowed for safe administration of supplementary
therapy such as enzyme replacement therapy or therapeutic gene
transfer to a different organ [35–37]. Using this method, animals
Figure 5. CD8
+ cellular infiltrates in adenoviral transduced livers. Liver sections from naı ¨ve or AAV-LacZ pre-treated C57BL/6 mice 10 days
after Ad-LacZ or Ad-GFP gene transfer. CD8
+ cells were stained red with AlexaFluorH 568 while b-gal
+ cells were stained green with AlexaFluorH 488.
GFP
+ cells were green by native fluorescence. A blue-pseudo color after image capture was used to show b-gal
+ cells from A. AAV-LacZ/Ad-LacZ and
B. Ad-LacZ livers, and the native green fluorescence was used to show GFP
+ cells from C. AAV-LacZ/Ad-GFP and D. Ad-GFP livers. E. The ratio of CD8
+
staining surrounding either b-gal or GFP producing hepatocytes was determined by capturing the images at 200X and analyzing with Image Pro
software. Data are average6SD for n=4 mice/experimental group. Arrows in A. point toward CD8
+ cells.
doi:10.1371/journal.pone.0006376.g005
Figure 6. Antibody formation against b-gal. Graphed are b-gal-
specific IgG1 titers as a function of time after Ad-lacZ gene transfer in
AAV-LacZ/Ad-LacZ and Ad-LacZ only transduced mice and, for
comparison, in AAV-LacZ only mice. Data are average6SD for n=4
mice/experimental group.
doi:10.1371/journal.pone.0006376.g006
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acid shingomyelinase, and other proteins [38]. Interestingly, these
are secreted or exocytosed proteins that have been expressed in
hepatocytes primarily for the purpose of systemic delivery for
correction of systemic protein deficiency or cross-correction
following up-take by other cell types.
Requirements for tolerance induction
Studies with a variety of vector systems have demonstrated that
requirements for tolerance induction by the hepatic route include
restriction of transgene expression to hepatocytes, use of a vector
with low innate immunity to reduce inflammatory signals, and lack
of transgene expression in professional APCs [38–40]. In this
context, hepatocyte-derived transgene expression leads to induc-
tion of CD4
+CD25
+FoxP3
+ Treg that suppress immune responses
to the transgene product [25,26,41]. Tolerance induction to F.IX
requires Treg and likely also activation induced cell death of F.IX-
specific effector T cells, which in combination may promote a shift
from an effector to a regulatory response [18,25]. Although AAV-
2 vectors transduce only a small portion of hepatocytes (typically
,5%), robust transgene expression can induce tolerance. In the
case of F.IX, we estimated that a systemic level of 30–50 ng/ml
plasma is required for tolerance induction [18]. It is therefore
conceivable that adequate secretion of a protein from few
hepatocytes results in delivery to and tolerogenic antigen
presentation by professional APCs, which may even be located
in lymphoid organs distal from the liver. Certainly, the spleen is a
site of processing of systemically circulating antigens. However,
our new data demonstrate that induction of immune tolerance by
AAV gene transfer does not require systemic expression.
Expression of a cytoplasmic protein in relatively few hepatocytes
(1–3%) was sufficient to completely protect from antibody
formation, to nearly eliminate activation of transgene product-
specific CD8
+ T cells, and to substantially reduce hepatotoxicity
and T cell infiltrates following insult with a first-generation Ad
vector.
Implications for antigen presentation and T cell
activations
In hepatic AAV-LacZ gene transfer, the expressed b-gal antigen
is not ignored but rather presented to T cells in a fashion that
results in Treg induction. In our previous studies with F.IX, we
Figure 7. ELISpot for frequency of IFN-c secreting lymphocytes following Ad-LacZ gene transfer. A. Frequencies in response to
stimulation with mock media, b-gal protein, b-gal CD8
+ T cell epitope, or adenoviral particles. Mice had received AAV-LacZ only (6 weeks earlier) or
AAV-LacZ followed by Ad-LacZ, or Ad-LacZ only, and assayed 14 days after Ad-LacZ administration. B. Positive control stimulation using 10 mg/ml of
Staphylococcal Enterotoxin B (SEB) super antigen. C. Frequencies in recipient mice of adoptively transferred CD4
+CD25
+ splenocytes from AAV-LacZ,
AAV-LacZ/Ad-LacZ, or Ad-LacZ transduced mice. Adoptive transfer was performed 10 days after Ad-LacZ gene transfer (i.e. 6 weeks plus 10 days after
AAV-LacZ gene transfer) to C57BL/6 mice. Recipient C57BL/6 mice were immunized the following day with the b-gal CD8
+ T cell epitope and assayed
10 days later. Animals receiving cells from naı ¨ve mice were included as an additional control group. D. Positive control stimulation using 10 mg/ml of
Staphylococcal Enterotoxin B (SEB) super antigen. A-D. In vitro stimulations were performed in triplicate for individual animals. Results are
average6SD for n=4 mice/experimental group.
doi:10.1371/journal.pone.0006376.g007
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+ T cells from AAV-F.IX hepatic
transduced mice were capable of suppressing the cellular immune
response to Ad-F.IX gene transfer following adoptive transfer [22].
Based on phenotyping of splenocytes of donor mice, we
hypothesized that CD4
+CD25
+FoxP3
+ Treg mediated suppres-
sion. Here, we demonstrated more directly that splenic
CD4
+CD25
+ Treg of tolerized mice are able to suppress the
transgene product-specific CD8
+ T cell response. Moreover, we
found that secondary gene transfer with an Ad vector expressing
the same transgene causes an increase in FoxP3
+ Treg frequency
in liver and spleen. This amplification of the regulatory response
likely controlled inflammation and liver damage, resulting in a 10-
fold reduction of CD8
+ T cell infiltrate in the liver despite the
presence of immunogenic adenoviral antigens. This suggests that
antigen expressed in the cytoplasm of a small portion of
hepatocytes can be effectively presented in a tolerogenic fashion,
thereby directing a Treg response that actively down-regulates
inflammatory T cells. Increase of Treg frequency and induction of
suppression upon Ad gene transfer was antigen-specific, i.e. linked
to the expression of the same b-gal antigen by the tolerizing and
the challenging vector. If the Ad encoded transgene was switched
to GFP, liver damage was identical to that induced by Ad-LacZ
gene transfer to naı ¨ve mice. The APC that is inducing the
suppressive T cell population remains to be identified. Direct
presentation of antigen by hepatocytes to T cells and indirect
pathways utilizing bone marrow-derived APCs or endothelial cells
have been proposed [42,43].
Implications for gene therapy
Even if the T cell response against Ad gene transfer was
completely suppressed in vivo, this vector still causes inflammation
and hepatotoxicity via a non-antigen-specific innate response
[44,45]. Despite these inflammatory signals, the destructive
response against Ad-LacZ transduced liver was suppressed enough
to achieve a 5-fold increase in the number of b-gal expressing
hepatocytes compared to AAV-LacZ only transduced livers (when
analyzed 1.5 months after secondary gene transfer, a time point
when expression from the Ad-LacZ vector had been completely
eliminated in control mice). In prior experiments with a F.IX
transgene, we found that secondary Ad-F.IX gene transfer to livers
of AAV-F.IX transduced mice increased the numbers of F.IX
expressing to .10% of hepatocytes at later time points [22]. This
may reflect higher expression levels of F.IX compared to b-gal
upon hepatic AAV-2 gene transfer, differences in the character-
istics of the transgene products, or differences between strains of
mice. Nonetheless, our new data show that systemic expression is
not a requirement for tolerance induction, albeit we cannot rule
out that systemic delivery further enhances tolerance. It will be of
interest to investigate whether expression of cytoplasmic or
secreted proteins may alter the relative contributions of Treg
Figure 8. Frequencies of CD4
+CD25
+Foxp3
+ Treg by flow cytometry. A. Example of analysis of splenocytes from a C57BL/6 mouse
transduced with AAV-LacZ and, 6 weeks later, with Ad-LacZ. B. Frequencies of CD4
+CD25
+Foxp3
+ splenocytes in AAV-LacZ, AAV2-LacZ/Ad-LacZ,
AAV2-LacZ/Ad-GFP, Ad-LacZ, or Ad-GFP transduced C57BL/6 mice. C. Frequencies of CD25
+GFP
+ intrahepatic lymphocytes (IHL) isolated from FoxP3
reporter mice (knock in mice for FoxP3-IRES-EGFP) after transduction with AAV-LacZ, AAV-LacZ/Ad-LacZ, or Ad-LacZ. A-C. All analyses were done 10
days after Ad gene transfer. Results are average6SD for n=4 mice/experimental group.
doi:10.1371/journal.pone.0006376.g008
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or anergy) to induction of unresponsiveness of the transgene
product-specific T cell population [46].
Recently, we found that hepatic AAV-F.IX gene transfer results
in tolerance induction to F.IX in multiple strains of mice over a
wide range of vector doses using a serotype 8 vector [47].
Combined, these observations are encouraging for development of
a more universal, hepatic gene transfer-based tolerance protocol
that is applicable to antigens with different cellular localizations
and less influenced by genetic factors inherent to the recipient of
gene transfer. Future protocols could incorporate secondary gene
transfer (following tolerance induction) using more effective
vectors that may otherwise be too immunogenic. Moreover,
improved AAV vectors may transduce a higher number of
hepatocytes, which has the potential to improve therapy and
tolerance induction [47].
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